Defense World
10 Apr 2026, 08:54 UTC · 30w ago
Impact · against what's priced in
Eli Lilly shows strong momentum driven by a significant revenue beat, aggressive EPS guidance for 2026, and institutional validation. While the institutional buying is nominal relative to the company's scale, the fundamental earnings trajectory provides a clear positive catalyst.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Eli Lilly reported quarterly revenue of $19.29 billion, beating analyst estimates of $17.85 billion and representing a 42.6% year-over-year increase.
More positive than 93% of claims this week
Eli Lilly set its FY 2026 EPS guidance between 33.500 and 35.000, which is substantially higher than the current fiscal year analyst average of 23.48 EPS.
Continue reading
5 related stories
The company reported a substantial revenue beat of $19.29 billion against $17.85 billion estimates and set FY 2026 EPS guidance (33.500-35.000) significantly above the analyst average of 23.48.
Read from the article alone
No priced-in read yet
The company experienced selling pressure from Douglas Lane & Associates LLC.
Read from the article alone
No priced-in read yet
The company experienced selling pressure from Douglas Lane & Associates LLC.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 85% of claims this week
Major financial institutions including JPMorgan, Bank of America, and Leerink Partners have raised their price targets for LLY, with targets reaching up to $1,300.
More positive than 62% of claims this week
Several institutional investors, including Apella Capital and Brighton Jones, increased their holdings in Eli Lilly during the fourth quarter.
So whatIncreased institutional ownership is positive, but the specific positions mentioned are relatively small compared to the company's $903 billion market cap.
More positive than 40% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company beat earnings and revenue estimates, saw significant institutional buying, and received multiple price target increases from major banks.
More negative than 76% of ticker scores this week
The company experienced selling pressure from Douglas Lane & Associates LLC.
More negative than 76% of ticker scores this week
The company experienced selling pressure from Douglas Lane & Associates LLC.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
2h ago
—
No price for LLY right now — the quote feed didn't answer.
LLY chart →—
No price for DEO right now — the quote feed didn't answer.
DEO chart →—
No price for IFF right now — the quote feed didn't answer.
IFF chart →
